Brokerages Set BeiGene, Ltd. (NASDAQ:BGNE) Price Target at $251.93

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $250.75.

Several research firms have recently commented on BGNE. TD Cowen boosted their price target on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Bank of America reduced their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research report on Tuesday. JPMorgan Chase & Co. boosted their price target on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Finally, Sanford C. Bernstein reduced their price target on BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research report on Wednesday, March 27th.

Insider Activity

In other news, CEO John Oyler sold 2,789 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $159.58, for a total value of $445,068.62. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO John Oyler sold 2,789 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $159.58, for a total value of $445,068.62. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Xiaobin Wu sold 1,459 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $159.79, for a total value of $233,133.61. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,683 shares of company stock valued at $1,056,089. Company insiders own 7.43% of the company’s stock.

Institutional Trading of BeiGene

A number of hedge funds have recently modified their holdings of BGNE. Headlands Technologies LLC purchased a new stake in shares of BeiGene in the first quarter worth about $50,000. Toronto Dominion Bank boosted its stake in shares of BeiGene by 166.4% in the third quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after buying an additional 208 shares during the last quarter. Benjamin F. Edwards & Company Inc. purchased a new position in BeiGene during the fourth quarter worth approximately $98,000. PNC Financial Services Group Inc. boosted its position in BeiGene by 123.9% during the third quarter. PNC Financial Services Group Inc. now owns 732 shares of the company’s stock worth $132,000 after purchasing an additional 405 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in BeiGene in the fourth quarter valued at approximately $183,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeiGene Price Performance

Shares of BGNE stock opened at $144.53 on Wednesday. BeiGene has a twelve month low of $126.97 and a twelve month high of $225.23. The stock has a market capitalization of $13.95 billion, a price-to-earnings ratio of -19.09 and a beta of 0.59. The stock has a fifty day simple moving average of $156.81 and a two-hundred day simple moving average of $157.82. The company has a current ratio of 2.08, a quick ratio of 1.84 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share for the quarter, topping the consensus estimate of ($3.07) by $0.66. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The business had revenue of $751.70 million during the quarter, compared to analysts’ expectations of $670.09 million. During the same period in the prior year, the business earned ($3.34) EPS. The business’s revenue for the quarter was up 67.9% compared to the same quarter last year. On average, analysts predict that BeiGene will post -8.2 EPS for the current fiscal year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.